Inozyme Pharma Inc. (INZY): Price and Financial Metrics
GET POWR RATINGS... FREE!
INZY Stock Price Chart Interactive Chart >
INZY Price/Volume Stats
| Current price | $2.42 | 52-week high | $7.98 |
| Prev. close | $2.26 | 52-week low | $0.99 |
| Day low | $2.20 | Volume | 570,664 |
| Day high | $2.54 | Avg. volume | 283,285 |
| 50-day MA | $1.54 | Dividend yield | N/A |
| 200-day MA | $3.03 | Market Cap | 97.75M |
Inozyme Pharma Inc. (INZY) Company Bio
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Latest INZY News From Around the Web
Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 – - Significant clinical and scientific milestones across ENPP1 Deficiency and ABCC6 Deficiency programs achieved in 2022 - BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and in |
Can you still get a good price for Inozyme Pharma Inc. (INZY) Shares at this point?Inozyme Pharma Inc. (NASDAQ:INZY) marked $1.05 per share on Friday, down from a previous closing price of $1.14. While Inozyme Pharma Inc. has underperformed by -7.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INZY fell by -84.89%, with highs and lows ranging from $7.98 to […] |
Is Inozyme Pharma Inc. (INZY) a opportunity to investors?As of Wednesday, Inozyme Pharma Inc.’s (NASDAQ:INZY) stock closed at $1.45, up from $1.26 the previous day. While Inozyme Pharma Inc. has overperformed by 15.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INZY fell by -78.74%, with highs and lows ranging from $8.27 to $1.19, […] |
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient population with ENPP1 Deficiency at 37,000 worldwide; 2,800 in North America, 4,100 in Europe and 900 in Japan - BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of p |
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap ConferenceBOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET. A replay of the fi |
INZY Price Returns
| 1-mo | 130.48% |
| 3-mo | 59.21% |
| 6-mo | -32.21% |
| 1-year | -63.77% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 130.48% |
| 2022 | -84.60% |
| 2021 | -66.96% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...